ESR1 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), which is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (EGFR2/HER2), represents 10–20% of total BC cases and accounts for approximately 30% of BC-related deaths [2].